Human Proprotein Convertase 9/PCSK9 Quantikine ELISA Kit

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Proprotein convertase subtilisin kexin 9 (PCSK9), also named neural apoptosis-regulated convertase 1 (NARC-1), is a member of the proteinase K subfamily of subtilisin-related serine endoproteases. The full-length protein has 692 amino acids, including a signal peptide, a pro- domain, and a catalytic domain. PCSK9 is highly expressed in the liver, intestine, and kidney. It is initially synthesized as a soluble 74 kDa precursor protein. In the endoplasmic reticulum, it undergoes autocatalytic intramolecular cleavage to generate a 14 kDa pro- domain and a 60 kDa catalytic domain. These two domains remain associated when PCSK9 is secreted outside the cells (1-3). The primary physiologic function of PCSK9 is to mediate the degradation of low density lipoprotein receptor (LDL R). Early observations indicated that gain-of-function missense mutations in the PCSK9 gene can cause an autosomal dominant form of hypercholesterolemia (4, 5). The expression of PCSK9 was observed to be up-regulated by the sterol regulatory element binding proteins (SREBPs), a family of transcription factors that are responsible for the upregulation of genes involved in cholesterol and fatty acid metabolism, such as the LDL R gene (6, 7). Further experimental evidence revealed that in mice, when the PCSK9 gene was knocked out, the number of LDL R in hepatocytes increased, whereas when PCSK9 was over-expressed, the amount of LDL R protein was reduced in the liver (8, 9). In humans, genetic analyses have shown that individuals who have nonsense or loss-of-function mutations in the PCSK9 gene have significantly lower plasma LDL cholesterol levels (10, 11). These investigations clearly indicated that PCSK9 plays a key role in reducing the hepatic LDL R levels. Recently, the underlying mechanism has been uncovered: under normal physiologic conditions, the LDL R is internalized on the cell surface and directed to the endosomes in order to be recycled back to the cell surface. PCSK9 binds to the EGF domain of the LDL R and prevents LDL R from being sorted to the endosomes. Instead, the PCSK9/LDL R complex is redistributed to the lysosomes for degradation (12-14). As such, PCSK9 regulates the amount of LDL R in the circulation and modulates cholesterol levels. Serum PCSK9 concentrations have been found to be directly associated with cholesterol levels (15, 16). Since individuals with loss-of-function PCSK9 mutations have strikingly reduced risk of coronary heart diseases, PCSK9 has become an attractive drug target in recent years (17, 18). One approach is to generate small molecules that are able to interfere with PCSK9 autoactivation and its interaction with LDL R. Other approaches aiming to reduce the amounts of PCSK9 in the circulation, such as small interfering RNAs (siRNAs), have also shown promise (19, 20).

We have publications tested in 5 confirmed species: Human, Mouse, Rat, Porcine, Transgenic Mouse.

Showing Publications 1 - 10 of 51. Show All 51 Publications. Collapse Publications.

Publications using DPC900	Applications	Species
Oguri, N;Gi, T;Nakamura, E;Furukoji, E;Goto, H;Maekawa, K;Tsuji, AB;Nishii, R;Aman, M;Moriguchi-Goto, S;Sakae, T;Azuma, M;Yamashita, A; Expression of fibroblast activation protein-? in human deep vein thrombosis Thrombosis research 2024-06-25 [PMID: 38955058] (Human)		Human
Zhang, B;Chuang, GY;Biju, A;Biner, D;Cheng, J;Wang, Y;Bao, S;Chao, CW;Lei, H;Liu, T;Nazzari, AF;Yang, Y;Zhou, T;Chen, SJ;Chen, X;Kong, WP;Ou, L;Parchment, DK;Sarfo, EK;SiMa, H;Todd, JP;Wang, S;Woodward, RA;Cheng, C;Rawi, R;Mascola, JR;Kwong, PD; Cholesterol reduction by immunization with a PCSK9 mimic Cell reports 2024-05-30 [PMID: 38819987] (Human)		Human
Bestas, B;Wimberger, S;Degtev, D;Madsen, A;Rottner, AK;Karlsson, F;Naumenko, S;Callahan, M;Touza, JL;Francescatto, M;Möller, CI;Badertscher, L;Li, S;Cerboni, S;Selfjord, N;Ericson, E;Gordon, E;Firth, M;Chylinski, K;Taheri-Ghahfarokhi, A;Bohlooly-Y, M;Snowden, M;Pangalos, M;Nuttall, B;Akcakaya, P;Sienski, G;Maresca, M; A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo Nature communications 2023-09-06 [PMID: 37673883] (Mouse)		Mouse
Ballantyne, CM;Ditmarsch, M;Kastelein, JJ;Nelson, AJ;Kling, D;Hsieh, A;Curcio, DL;Maki, KC;Davidson, MH;Nicholls, SJ; Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial Journal of clinical lipidology 2023-05-31 [PMID: 37277261] (Human)		Human
A Larrea-Seb, C Trenti, S Jebari-Ben, S Bertolini, S Calandra, EA Negri, E Bonelli, A Benito-Vic, L Uraga-Grac, C Martín, T Fasano Functional Characterization of p.(Arg160Gln) PCSK9 Variant Accidentally Found in a Hypercholesterolemic Subject International Journal of Molecular Sciences, 2023-02-07;24(4):. 2023-02-07 [PMID: 36834740] (Human)		Human
Atreya MR, Cvijanovich NZ, Fitzgerald JC et al. Detrimental effects of PCSK9 loss-of-function in the pediatric host response to sepsis are mediated through independent influence on Angiopoietin-1 Research square 2023-02-03 [PMID: 36778250] (Human)		Human
MK ?widerska, A Mostowska, D Skrypnik, PP Jagodzi?sk, P Bogda?ski, AE Grzegorzew Energy Homeostasis Gene Nucleotide Variants and Survival of Hemodialysis Patients-A Genetic Cohort Study Journal of Clinical Medicine, 2022-09-18;11(18):. 2022-09-18 [PMID: 36143124] (Human)		Human
F Spannella, F Giulietti, R Galeazzi, A Passarelli, S Re, C Di Pentima, M Allevi, P Magni, R Sarzani Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Inversely Associated with N-Terminal Pro B-Type Natriuretic Peptide in Older Men and Women Biomedicines, 2022-08-12;10(8):. 2022-08-12 [PMID: 36009507] (Human)		Human
LS Silva-Berm, A Vargas-Vil, CA Sánchez-Va, AC Palacio, AF Buitrago, CO Mendivil Peri-event plasma PCSK9 and hsCRP after an acute myocardial infarction correlate with early deterioration of left ventricular ejection fraction: a cohort study Oncogene, 2022-07-21;21(1):61. 2022-07-21 [PMID: 35864531] (Human)		Human
J Baran, ? Niewiara, J Podolec, M Siedli?ski, E Józefczuk, A Bernacik, R Badacz, T Przew?ocki, P Pieni??ek, K ?mudka, J Legutko, A Kab?ak-Zie Serum and Vascular Stiffness Biomarkers Associated with the Severity of Degenerative Aortic Valve Stenosis and Cardiovascular Outcomes Oncogene, 2022-06-17;9(6):. 2022-06-17 [PMID: 35735822] (Human)		Human
C Lammi, EMA Fassi, J Li, M Bartolomei, G Benigno, G Roda, A Arnoldi, G Grazioso Computational Design and Biological Evaluation of Analogs of Lupin Peptide P5 Endowed with Dual PCSK9/HMG-CoAR Inhibiting Activity Pharmaceutics, 2022-03-18;14(3):. 2022-03-18 [PMID: 35336039] (Human)		Human
PF Lebeau, JH Byun, K Platko, P Saliba, M Sguazzin, ME MacDonald, G Paré, GR Steinberg, LJ Janssen, SA Igdoura, MA Tarnopolsk, SR Wayne Chen, NG Seidah, J Magolan, RC Austin Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance Nature Communications, 2022-02-09;13(1):770. 2022-02-09 [PMID: 35140212] (Human)		Human
T Metzner, DR Leitner, K Mellitzer, A Beck, H Sourij, T Stojakovic, G Reishofer, W März, U Landmesser, H Scharnagl, H Toplak, G Silbernage Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study Biomedicines, 2022-01-17;10(1):. 2022-01-17 [PMID: 35052871] (Human)		Human
L Canclini, AM Malvandi, P Uboldi, N Jabnati, L Grigore, A Zambon, A Baragetti, AL Catapano The Association of Proprotein Convertase Subtilisin/Kexin Type 9 to Plasma Low-Density Lipoproteins: An Evaluation of Different Methods Metabolites, 2021-12-10;11(12):. 2021-12-10 [PMID: 34940619] (Human)		Human
MM Liu, J Peng, YL Guo, CG Zhu, NQ Wu, RX Xu, Q Dong, JJ Li Relations of physical signs to genotype, lipid and inflammatory markers, coronary stenosis or calcification, and outcomes in patients with heterozygous familial hypercholesterolemia Journal of Translational Medicine, 2021-12-07;19(1):498. 2021-12-07 [PMID: 34876165] (Human)		Human
J Peng, MM Liu, HH Liu, YL Guo, NQ Wu, Q Dong, J Qian, KF Dou, CG Zhu, JJ Li Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study Thrombosis journal, 2021-11-22;19(1):90. 2021-11-22 [PMID: 34809656] (Human)		Human
B Vergès, J Hassid, A Rouland, B Bouillet, I Simoneau, JM Petit, L Duvillard Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins Diabetes & metabolism, 2021-09-19;0(0):101284. 2021-09-19 [PMID: 34551355] (Human)		Human
C Melexopoul, S Marinaki, E Oikonomou, MJ Bonios, P Theofilis, A Miliou, G Siasos, D Tousoulis, JN Boletis PCSK9 and inflammatory biomarkers in the early post kidney transplantation period European review for medical and pharmacological sciences, 2021-07-01;25(14):4762-4772. 2021-07-01 [PMID: 34337724] (Human)		Human
E Dounousi, C Tellis, P Pavlakou, A Duni, V Liakopoulo, PB Mark, A Papagianni, AD Tselepis Association between PCSK9 Levels and Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction in a Population of Nondialysis Chronic Kidney Disease Patients Oxidative Medicine and Cellular Longevity, 2021-07-20;2021(0):6677012. 2021-07-20 [PMID: 34336112] (Human)		Human
T Rothgangl, MK Dennis, PJC Lin, R Oka, D Witzigmann, L Villiger, W Qi, M Hruzova, L Kissling, D Lenggenhag, C Borrelli, S Egli, N Frey, N Bakker, JA Walker, AP Kadina, DV Victorov, M Pacesa, S Kreutzer, Z Kontarakis, A Moor, M Jinek, D Weissman, M Stoffel, R van Boxtel, K Holden, N Pardi, B Thöny, J Häberle, YK Tam, SC Semple, G Schwank In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels Nature Biotechnology, 2021-05-19;0(0):. 2021-05-19 [PMID: 34012094] (Human)		Human
C Lammi, G Aiello, C Bollati, J Li, M Bartolomei, G Ranaldi, S Ferruzza, EMA Fassi, G Grazioso, Y Sambuy, A Arnoldi Trans-Epithelial Transport, Metabolism, and Biological Activity Assessment of the Multi-Target Lupin Peptide LILPKHSDAD (P5) and Its Metabolite LPKHSDAD (P5-Met) Nutrients, 2021-03-05;13(3):. 2021-03-05 [PMID: 33808034] (Human)		Human
MZ Ciric, M Ostojic, I Baralic, J Kotur-Stev, BI Djordjevic, S Markovic, S Zivkovic, I Stankovic Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy Nutrients, 2021-03-10;13(3):. 2021-03-10 [PMID: 33802219] (Human)		Human
JPP Silvino, MG Carvalho, EA Reis, APL Mota, KB Gomes, RCF Duarte, MCJ Guimarães, MCR Sousa, PS Azevedo, IFO Silva Familial hypercholesterolemia: Is there a role for PCSK9 and thrombin generation? Thrombosis Research, 2021-02-16;200(0):156-163. 2021-02-16 [PMID: 33626480] (Human)		Human
B Ibold, J Tiemann, I Faust, U Ceglarek, J Dittrich, TGMF Gorgels, AAB Bergen, O Vanakker, M Van Gils, C Knabbe, D Hendig Genetic deletion of Abcc6 disturbs cholesterol homeostasis in mice Scientific Reports, 2021-01-22;11(1):2137. 2021-01-22 [PMID: 33483533] (Human)		Human
JA Levine, C Oleaga, M Eren, AP Amaral, M Shang, E Lux, SS Khan, SJ Shah, Y Omura, N Pamir, J Hay, G Barish, T Miyata, H Tavori, S Fazio, DE Vaughan Role of PAI-1 in hepatic steatosis and dyslipidemia Scientific Reports, 2021-01-11;11(1):430. 2021-01-11 [PMID: 33432099] (Human)		Human
J Peng, MM Liu, JL Jin, YX Cao, YL Guo, NQ Wu, CG Zhu, Q Dong, J Sun, RX Xu, JJ Li Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study Cardiovasc Diabetol, 2020-10-06;19(1):167. 2020-10-06 [PMID: 33023603] (Human)		Human
S Fasolato, S Pigozzo, P Pontisso, P Angeli, M Ruscica, E Savarino, S De Martin, MG Lupo, N Ferri PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma J Clin Med, 2020-09-28;9(10):. 2020-09-28 [PMID: 32998342] (Human)		Human
K Chemello, S Beeské, TT Trang Tran, V Blanchard, EF Villard, B Poirier, JC Le Bail, G Dargazanli, S Ho-Van-Gui, D Boulay, O Bergis, MP Pruniaux, M Croyal, P Janiak, E Guillot, G Lambert Lipoprotein(a) Cellular Uptake Ex�Vivo and Hepatic Capture In�Vivo Is Insensitive to PCSK9 Inhibition With Alirocumab JACC Basic Transl Sci, 2020-05-06;5(6):549-557. 2020-05-06 [PMID: 32613143] (Human)		Human
E Dozio, M Ruscica, E Vianello, C Macchi, C Sitzia, G Schmitz, L Tacchini, MM Corsi Roma PCSK9 Expression in Epicardial Adipose Tissue: Molecular Association with Local Tissue Inflammation Mediators Inflamm., 2020-06-04;2020(0):1348913. 2020-06-04 [PMID: 32565719] (Human)		Human
CJ Cui, JL Jin, LN Guo, J Sun, NQ Wu, YL Guo, G Liu, Q Dong, JJ Li Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1&alpha and activating FoxO3a J Transl Med, 2020-05-12;18(1):195. 2020-05-12 [PMID: 32398139] (Human)		Human
JA Krahel, A Baran, TW Kami?ski, M Maciaszek, I Flisiak Methotrexate Decreases the Level of PCSK9-A Novel Indicator of the Risk of Proatherogenic Lipid Profile in Psoriasis. The Preliminary Data J Clin Med, 2020-03-26;9(4):. 2020-03-26 [PMID: 32225075] (Human)		Human
MG Lupo, N Biancoross, E Brilli, G Tarantino, MP Adorni, G Vivian, M Salvalaio, S Dall'Acqua, S Sut, C Neutel, H Chen, A Bressan, E Faggin, M Rattazzi, N Ferri Cholesterol-Lowering Action of a Novel Nutraceutical Combination in Uremic Rats: Insights into the Molecular Mechanism in a Hepatoma Cell Line Nutrients, 2020-02-09;12(2):. 2020-02-09 [PMID: 32050453] (Human)		Human
YX Cao, JL Jin, D Sun, HH Liu, YL Guo, NQ Wu, RX Xu, CG Zhu, Q Dong, J Sun, JJ Li Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy J Transl Med, 2019-11-11;17(1):367. 2019-11-11 [PMID: 31711505] (Human)		Human
C Li, Z Hu, W Zhang, J Yu, Y Yang, Z Xu, H Luo, X Liu, Y Liu, C Chen, Y Cai, X Xia, X Zhang, DZ Wang, G Wu, C Zeng Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER Sci Rep, 2019-05-22;9(1):7693. 2019-05-22 [PMID: 31118464] (Human)		Human
A Carreras, LS Pane, R Nitsch, K Madeyski-B, M Porritt, P Akcakaya, A Taheri-Gha, E Ericson, M Bjursell, M Perez-Alca, F Seeliger, M Althage, R Knöll, R Hicks, LM Mayr, R Perkins, D Lindén, J Borén, M Bohlooly-Y, M Maresca In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model BMC Biol., 2019-01-15;17(1):4. 2019-01-15 [PMID: 30646909] (Transgenic Mouse)		Transgenic Mouse
KR Genga, C Lo, MS Cirstea, FS Leitao Fil, KR Walley, JA Russell, A Linder, GA Francis, JH Boyd Impact of PCSK9 loss-of-function genotype on 1-year mortality and recurrent infection in sepsis survivors EBioMedicine, 2018-11-23;0(0):. 2018-11-23 [PMID: 30473376] (Human)		Human
P Akcakaya, ML Bobbin, JA Guo, J Malagon-Lo, K Clement, SP Garcia, MD Fellows, MJ Porritt, MA Firth, A Carreras, T Baccega, F Seeliger, M Bjursell, SQ Tsai, NT Nguyen, R Nitsch, LM Mayr, L Pinello, M Bohlooly-Y, MJ Aryee, M Maresca, JK Joung In vivo CRISPR editing with no detectable genome-wide off-target mutations Nature, 2018-09-12;0(0):. 2018-09-12 [PMID: 30209390] (Mouse)		Mouse
C Vlachopoul, I Koutagiar, D Terentes-P, I Skoumas, A Rigatou, A Miliou, AN Skliros, S Pantou, K Filis, D Tousoulis Relationship of PCSK9 levels with indices of vascular function and subclinical atherosclerosis in patients with familial dyslipidaemias Hellenic J Cardiol, 2018-05-25;0(0):. 2018-05-25 [PMID: 29807195] (Human)		Human
P Lebeau, K Platko, AA Al-Hashimi, JH Byun, Š Lhoták, N Holzapfel, G Gyulay, SA Igdoura, D Cool, B Trigatti, NG Seidah, RC Austin Loss-of-function PCSK9 mutants evade the unfolded protein response sensor, GRP78, and fail to induce endoplasmic reticulum stress when retained J. Biol. Chem., 2018-03-28;0(0):. 2018-03-28 [PMID: 29593095] (Human)		Human
F Yuan, L Guo, KH Park, JR Woollard, K Taek-Geun, K Jiang, T Melkamu, B Zang, SL Smith, SC Fahrenkrug, FD Kolodgie, A Lerman, R Virmani, LO Lerman, DF Carlson Ossabaw Pigs With a PCSK9 Gain-of-Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies J Am Heart Assoc, 2018-03-23;7(6):. 2018-03-23 [PMID: 29572319] (Porcine)		Porcine
R Papazyan, X Liu, J Liu, B Dong, EM Plummer, RD Lewis, JD Roth, MA Young FXR Activation by Obeticholic Acid or Non-Steroidal Agonists Induces a Human-Like Lipoprotein Cholesterol Change in Mice with Humanized Chimeric Liver J. Lipid Res., 2018-03-20;0(0):. 2018-03-20 [PMID: 29559521] (Mouse)		Mouse
M Zimmer, P Bista, EL Benson, DY Lee, F Liu, D Picarella, RB Vega, CB Vu, M Yeager, M Ding, G Liang, JD Horton, R Kleemann, T Kooistra, MC Morrison, PY Wielinga, JC Milne, MR Jirousek, AJ Nichols CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice Hepatol Commun, 2017-05-12;1(4):311-325. 2017-05-12 [PMID: 29404461] (Human)		Human
C Ricci, M Ruscica, M Camera, L Rossetti, C Macchi, A Colciago, I Zanotti, MG Lupo, MP Adorni, AFG Cicero, F Fogacci, A Corsini, N Ferri PCSK9 induces a pro-inflammatory response in macrophages Sci Rep, 2018-02-02;8(1):2267. 2018-02-02 [PMID: 29396513] (Human)		Human
MV Zanni, LA Stone, M Toribio, DE Rimmelin, J Robinson, TH Burdo, K Williams, KV Fitch, J Lo, SK Grinspoon Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV Open Forum Infect Dis, 2017-10-14;4(4):ofx227. 2017-10-14 [PMID: 29226174] (Human)		Human
C Gustafsen, D Olsen, J Vilstrup, S Lund, A Reinhardt, N Wellner, T Larsen, CBF Andersen, K Weyer, JP Li, PH Seeberger, S Thirup, P Madsen, S Glerup Heparan sulfate proteoglycans present PCSK9 to the LDL receptor Nat Commun, 2017-09-11;8(1):503. 2017-09-11 [PMID: 28894089] (Human)		Human
M Ruscica, N Ferri, F Fogacci, M Rosticci, M Botta, S Marchiano, P Magni, S D'Addato, M Giovannini, C Borghi, AFG Cicero Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study J Am Heart Assoc, 2017-05-03;6(5):. 2017-05-03 [PMID: 28468788] (Human)		Human
Paul Lebeau Endoplasmic reticulum stress and Ca2+ depletion differentially modulate the sterol-regulatory protein PCSK9 to control lipid metabolism J. Biol. Chem, 2016-12-01;0(0):. 2016-12-01 [PMID: 27909053] (Human)		Human
SH Yang, Y Du, S Li, Y Zhang, RX Xu, CG Zhu, YL Guo, NQ Wu, Q Dong, J Sun, JJ Li Plasma PCSK9 level is unrelated to blood pressure and not associated independently with carotid intima-media thickness in hypertensives Hypertens Res, 2016-04-14;0(0):. 2016-04-14 [PMID: 27075829] (Human)		Human
Loregger A, Cook E, Nelson J, Moeton M, Sharpe L, Engberg S, Karimova M, Lambert G, Brown A, Zelcer N A MARCH6 and IDOL E3 Ubiquitin Ligase Circuit Uncouples Cholesterol Synthesis from Lipoprotein Uptake in Hepatocytes. Mol Cell Biol, 2015-11-02;36(2):285-94. 2015-11-02 [PMID: 26527619] (Human)		Human
Almontashiri N, Vilmundarson R, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi A, Chen H, Stewart A Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS ONE, 2014-09-02;9(9):e106294. 2014-09-02 [PMID: 25180781] (Human)		Human
Zhang Y, Liu J, Li S, Xu R, Sun J, Li J Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: single or in combination study in rats. Lipids Health Dis, 2014-02-18;13(0):35. 2014-02-18 [PMID: 24533584] (Rat)		Rat
Show All 51 Publications. Collapse Publications.

Array DPC900

• Fibroblast Activation Protein alpha/FAP Antibodies
• Fibroblast Activation Protein alpha/FAP Lysate
• Fibroblast Activation Protein alpha/FAP ELISAs
• Fibroblast Activation Protein alpha/FAP Proteins and Enzymes